Giving a skin cancer diagnosis to a patient is never easy. The word “cancer” is a scary word for any patient to hear. Sadly, one in five Americans will develop skin cancer over the course of their lifetime and 40 to 50 percent of Americans who live to age 65 will have either basal cell carcinoma or squamous cell carcinoma at least once. Basal cell cancer is the most common form of skin cancer.
While patients facing basal cell cancer have multiple choices available for the treatment of their skin cancer, are you offering your patients the best treatment available? The majority of treatment options for basal cell cancer involve a surgical procedure of some type, whether excisional surgery, electrosurgery, cryosurgery, laser surgery or Mohs micrographic surgery.
What if you could provide your patients facing skin cancer with a treatment option that is painless, safe and effective to treat his or her basal cell carcinoma?
The SRT-100™ is that option.
Sensus Healthcare’s SRT-100™ delivers a precise, calibrated dose of Superficial Radio Therapy that only goes skin deep. This low-dose of Superficial Radio Therapy safely destroys non-melanoma skin cancer (such as basal cell carcinoma) without damaging healthy surrounding tissue. There is no need for anesthesia, no cutting or stitching, less risk for infection, and no need for patients to undergo reconstructive plastic surgery to repair surgical scars. With the SRT-100™, patients heal quickly from their basal cell cancer treatment with no downtime or lifestyle restrictions following the procedure.
Performed right in your office, Superficial Radio Therapy with the SRT-100™ delivers optimum results to treat basal cell carcinoma without the negative side effects of invasive treatments. This treatment is ideal for your patients diagnosed with basal cell carcinoma who also have health risks that prevent them from undergoing surgical treatment, or patients who wish to avoid the pain and scarring associated with surgery.
For the physician, SRT-100™ offers many unique features including a broad range of motion; compact, mobile design; precise and accurate x-ray delivery; variable applicator sizes; and replaceable contact shields.
Sensus Healthcare’s SRT-100™ has cure rates comparable to those of surgical skin cancer treatment options and has been cleared by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma. It is ideal for private dermatology and oncology practices, as well as hospitals and multi-locale healthcare providers.
Give your patients a non-surgical, painless and effective basal cell cancer treatment. Contact Sensus Healthcare today to learn more about the SRT-100™.
